Navigation Links
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
Date:3/23/2009

BEIJING, March 23 /PRNewswire/ -- BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.

"After a successful collaboration involving discovery chemistry, ADMET, and DMPK, AstraZeneca has expanded its collaboration with BioDuro to leverage the strengths of its team to help develop new therapeutics," said Lena Martensson Director of Strategic Planning and Business Development.

"BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at AstraZeneca to develop new clinical compounds for Respiratory and Inflammation indications. This partnership demonstrates the strength of our innovation, quality, and our fully integrated R&D service platform," commented John Oyler, Chief Executive Officer and co-founder of BioDuro LLC.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

About BioDuro

BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of 580 in Beijing, China. BioDuro combines western pharmaceutical company quality and professionalism, with entrepreneurial, innovative biotech culture, to leverage its talented, hard-working Chinese scientists. BioDuro's clients are over 40 pharmaceutical and biotechnology companies, including 10 of the top-12. BioDuro's services span the entire range of drug discovery and development, from discovery chemistry, discovery biology, early ADMET, DMPK, through pharmacology and drug safety and evaluation.

*ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity

**DMPK: Drug Metabolism and Pharmacokinetics


'/>"/>
SOURCE BioDuro, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation
2. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
3. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
4. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
5. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
6. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
7. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
8. Melior Enters Research Collaboration with AstraZeneca
9. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
10. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
11. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
(Date:1/19/2017)... 18, 2017 Acupath Laboratories, Inc., a leading ... of an Executive Committee that will guide the company,s ... John Cucci , a 15-year veteran of the ... Business Development to Chief Sales Officer .  Prior ... in senior sales leadership roles at several leading lab ...
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place ... in Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
Breaking Biology News(10 mins):